Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

The marine environment is a rich source of biologically active molecules for the treatment of
human diseases, especially cancer. The adaptation to unique environmental conditions led …

Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown
promising preliminary data in lung cancer with impressive response rates and survival …

The TAM receptor family of TYRO3, AXL and MERTK regulates tissue and immune
homeostasis. Aberrant TAM receptor signalling has been linked to a range of diseases …

Lung cancer has the highest incidence of morbidity and mortality throughout the globe. A
large number of patients are diagnosed with lung cancer at the later stages of the disease …

Cancer has always been a threat to human health with its high morbidity and mortality rates.
Traditional therapy, including surgery, chemotherapy and radiotherapy, plays a key role in …

Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its
current applications include the first-line setting, second-line setting, as well as the adjuvant …

Antibody drug conjugates (ADCs) are an emerging class of therapeutics that consist of a
cytotoxic agent linked covalently to an antibody, which is directed toward a specific cell …

AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family.
Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is …